<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801280</url>
  </required_header>
  <id_info>
    <org_study_id>CERL 080A DE 20 T</org_study_id>
    <secondary_id>2010-021275-92</secondary_id>
    <nct_id>NCT01801280</nct_id>
  </id_info>
  <brief_title>Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS</brief_title>
  <official_title>Single Center, Open Labeled, Cross-over Study in Maintenance Renal Transplant Patients to Evaluate Pnatoprazole Influence on MPA Bioavailabiliy Administered as Mycophenolate Mofetil and Enteric Coated Mycophenolate Sodium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klemens Budde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pharmacokinetic study is to examine a possible drug-drug interaction of
      Pantoprazole on the bioavailability mycophenolic acid administered as either Mycophenolate
      mofetil (Cellcept(R) or Mycophenolate Sodium; EC-MPS (Myfortic (R) in stable renal allograft
      recipients under maintenance immunosuppressive therapy (cyclosporine +/- low dose
      glucocorticoids).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-normalized AUC of Mycophenolic Acid</measure>
    <time_frame>Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for PK/PD analysis will be collected. On the next day new treatment starts. There are 4 study visits at the study center. Duration will be approximately 12hours</time_frame>
    <description>Bioavailability (12h AUC) of mycophenolic acid in renal transplant patients after administration of MMF+/-PAN and EC-MPS+/-PAN
For evaluation of pharmacokinetic and pharmacodynamic parameters blood will be collected before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after drug intake.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Bioavailability</condition>
  <condition>Drug Interactions</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil (C)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil+Pantoprazole (C + P)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks.
Pantoprazole 40mg tablet (P) once a day in the morning for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate sodium (M)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate sodium+Pantoprazole (M+ P)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole 40mg tablet (P) once a day in the morning for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate sodium</intervention_name>
    <description>Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.</description>
    <arm_group_label>Mycophenolate sodium (M)</arm_group_label>
    <arm_group_label>Mycophenolate sodium+Pantoprazole (M+ P)</arm_group_label>
    <other_name>Myfortic®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>Daily dose: 40mg. Application together with CellCept® or Myfortic® .</description>
    <arm_group_label>Mycophenolate mofetil+Pantoprazole (C + P)</arm_group_label>
    <arm_group_label>Mycophenolate sodium+Pantoprazole (M+ P)</arm_group_label>
    <other_name>Pantozol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .</description>
    <arm_group_label>Mycophenolate mofetil (C)</arm_group_label>
    <arm_group_label>Mycophenolate mofetil+Pantoprazole (C + P)</arm_group_label>
    <other_name>Cellcept®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &gt;18 years old

          -  patients who are under stable immunosuppressive therapy for at least one month with
             ciclosporin, EC-MPS or MMF +/- corticosteroids

          -  renal transplantation, at least 6 months prior study inclusion

          -  suitable and willing to switch treatment according to the study plan

          -  women of childbearing potential must have a negative serum pregnancy test before study
             start and effective contraception must be used (method with PEARL index &lt; 1%)

        Exclusion Criteria:

          -  patients with renal function &lt; 30ml/min (estimated by Cockcroft Gault formula)

          -  patients who are not on stable treatment with enzyme inductors or enzymes inhibitors
             for &lt;1month before study entry

          -  patients who take medication which is known for interfering with MPA absorption for
             &lt;1month before study entry

          -  known anamnestic hypersensitivity to one of the investigational products or drugs with
             similar chemical structure and to other components of the investigational products,
             respectively

          -  patients on treatment with clopidogrel

          -  acute rejection &lt; 1 month before study inclusion

          -  patients who are HIV positive, hepatitis C virus (HCV) positive, HBsAg positive

          -  patients with gastrointestinal disorders which could affect resorption

          -  pregnancy and/or lactation

          -  drug or alcohol abuse in patient's history

          -  patients with history of psychological illness or condition, which might interfere
             with the ability to understand the requirements, consequences, possible outcome of the
             study and patients who are not willing to give valid informed consent

          -  patients with insufficient co-operation with the clinical investigator (e.g. suspicion
             of non-compliance)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klemens Budde, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Hospital Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2013</study_first_posted>
  <results_first_submitted>December 17, 2014</results_first_submitted>
  <results_first_submitted_qc>July 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2016</results_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Klemens Budde</investigator_full_name>
    <investigator_title>Professor Dr Klemens Budde</investigator_title>
  </responsible_party>
  <keyword>immunosuppressive medication</keyword>
  <keyword>mycophenolic acid</keyword>
  <keyword>interaction</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>pantoprazole</keyword>
  <keyword>renal transplant patients</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment lastet between January 2012 - March 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence A</title>
          <description>st period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d.
nd period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d.
rd period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
th period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.</description>
        </group>
        <group group_id="P2">
          <title>Sequence B</title>
          <description>st period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d.
nd period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
rd period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
th period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d.</description>
        </group>
        <group group_id="P3">
          <title>Sequence C</title>
          <description>st period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
nd period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
rd period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d.
th period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d.</description>
        </group>
        <group group_id="P4">
          <title>Sequence D</title>
          <description>st period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
nd period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d.
rd period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d.
th period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">Each period lasted 10-14 weeks</participants>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence A</title>
          <description>st period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d.
nd period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d.
rd period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
th period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.</description>
        </group>
        <group group_id="B2">
          <title>Sequence B</title>
          <description>st period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d.
nd period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
rd period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
th period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d.</description>
        </group>
        <group group_id="B3">
          <title>Sequence C</title>
          <description>st period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
nd period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
rd period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d.
th period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d.</description>
        </group>
        <group group_id="B4">
          <title>Sequence D</title>
          <description>st period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.
nd period: Mycophenolate mofetil (MMF) tablet (500, 750 or 1000mg) b.i.d. every 12 hours for 10-14d.
rd period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d.
th period: Mycophenolate sodium (EC-MPS) tablet (720, 1080, 1440) b.i.d. every 12 hours for 10-14d. Pantoprazole 40mg tablet (PAN) each for 10-14d.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at transplantation</description>
          <units>y</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="12"/>
                    <measurement group_id="B2" value="42" spread="14"/>
                    <measurement group_id="B3" value="33" spread="17"/>
                    <measurement group_id="B4" value="43" spread="14"/>
                    <measurement group_id="B5" value="44" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at study enrollment</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="11"/>
                    <measurement group_id="B2" value="46" spread="16"/>
                    <measurement group_id="B3" value="44" spread="15"/>
                    <measurement group_id="B4" value="51" spread="19"/>
                    <measurement group_id="B5" value="51" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose-normalized AUC of Mycophenolic Acid</title>
        <description>Bioavailability (12h AUC) of mycophenolic acid in renal transplant patients after administration of MMF+/-PAN and EC-MPS+/-PAN
For evaluation of pharmacokinetic and pharmacodynamic parameters blood will be collected before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after drug intake.</description>
        <time_frame>Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for PK/PD analysis will be collected. On the next day new treatment starts. There are 4 study visits at the study center. Duration will be approximately 12hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil (MMF)</title>
            <description>Mycophenolate mofetil (MMF) tablet twice a day every 12 hours for two weeks.
Mycophenolate mofetil daily dose: 1000mg, 1500mg, 2000mg.</description>
          </group>
          <group group_id="O2">
            <title>MMF+PAN</title>
            <description>Mycophenolate mofetil (MMF) tablet twice a day every 12 hours for two weeks.
Mycophenolate mofetil daily dose: 1000mg, 1500mg, 2000mg.
Pantoprazole daily dose: 40mg once in the morning together with Mycophenolate mofetil.
Pantoprazole tablet (PAN) once a day in the morning for two weeks.</description>
          </group>
          <group group_id="O3">
            <title>EC-MPS</title>
            <description>Mycophenolate sodium (EC-MPS) tablet twice a day every 12 hours for two weeks.
Mycophenolate sodium daily dose: 720mg, 1080mg, 1440mg.</description>
          </group>
          <group group_id="O4">
            <title>EC-MPS + PAN</title>
            <description>Mycophenolate sodium (EC-MPS) tablet twice a day every 12 hours for two weeks.
Mycophenolate sodium daily dose: 720mg, 1080mg, 1440mg.
Pantoprazole daily dose: 40mg once in the morning together with Mycophenolate sodium.
Pantoprazole tablet (PAN) once a day in the morning for two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized AUC of Mycophenolic Acid</title>
          <description>Bioavailability (12h AUC) of mycophenolic acid in renal transplant patients after administration of MMF+/-PAN and EC-MPS+/-PAN
For evaluation of pharmacokinetic and pharmacodynamic parameters blood will be collected before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after drug intake.</description>
          <units>mg*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="18"/>
                    <measurement group_id="O2" value="38" spread="18"/>
                    <measurement group_id="O3" value="43" spread="19"/>
                    <measurement group_id="O4" value="46" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected at every study visit. No follow up data.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mycophenolate Mofetil (MMF)</title>
          <description>Mycophenolate mofetil (MMF) tablet twice a day every 12 hours for two weeks.
Mycophenolate mofetil daily dose: 1000mg, 1500mg, 2000mg.</description>
        </group>
        <group group_id="E2">
          <title>MMF + PAN</title>
          <description>Mycophenolate mofetil (MMF) tablet twice a day every 12 hours for two weeks.
Mycophenolate mofetil daily dose: 1000mg, 1500mg, 2000mg.
Pantoprazole daily dose: 40mg once in the morning together with Mycophenolate mofetil.
Pantoprazole tablet (PAN) once a day in the morning for two weeks.</description>
        </group>
        <group group_id="E3">
          <title>EC-MPS</title>
          <description>Mycophenolate sodium (EC-MPS) tablet twice a day every 12 hours for two weeks.
Mycophenolate sodium daily dose: 720mg, 1080mg, 1440mg.</description>
        </group>
        <group group_id="E4">
          <title>EC-MPS + PAN</title>
          <description>Mycophenolate sodium (EC-MPS) tablet twice a day every 12 hours for two weeks.
Mycophenolate sodium daily dose: 720mg, 1080mg, 1440mg.
Pantoprazole daily dose: 40mg once in the morning together with Mycophenolate sodium.
Pantoprazole tablet (PAN) once a day in the morning for two weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Noro virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Olesja Rissling</name_or_title>
      <organization>Charité University Hospital - Department of Nephrology</organization>
      <phone>+49 30 450 514 153</phone>
      <email>olesja.rissling@charite.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

